Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Causality Assessment in Practice Pharmaceutical Industry Perspective. Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd."

Transcription

1 Causality Assessment in Practice Pharmaceutical Industry Perspective Lachlan MacGregor Senior Safety Scientist F. Hoffmann-La Roche Ltd., Basel

2 Disclaimer: The opinions expressed in this presentation are those of the author, and do not reflect those of F. Hoffmann-La Roche Ltd.

3 Overview of presentation Causality and case processing Guidance from regulators and CIOMS Naranjo algorithm at Roche Language to express uncertainty Reaching definitive conclusions about drug-event pairs Conclusions Final thoughts

4 Causality and case processing Spontaneous case reports Reporter s assessment of causality is often not explicit Roche standard AE form: Reporter selects `related, `not related `unknown or `not provided for each drug-event pair. Interpretation of `related is left to the reporter Spontaneously reported events are considered related, for the purpose of case processing and regulatory reporting, unless reporter says `not related Study case reports Investigator codes events as related or not related to the study drug Some instruction for the investigator are provided in the study protocol SUSAR: `Reaction implies `related

5 Instructions for investigators Typical study protocol provides information like this: Investigators should use their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether or not an adverse event is considered to be related to the study drug, indicating "yes" or "no" accordingly. The following guidance should be taken into consideration: Temporal relationship of event onset to the initiation of study drug Course of the event, considering especially the effects of dose reduction, discontinuation of study drug, or re-introduction of study drug (where applicable) Known association of the event with the study drug or with similar treatments Known association of the event with the disease under study Presence of risk factors in the patient or use of concomitant medications known to increase the occurrence of the event Presence of non treatment-related factors that are known to be associated with the occurrence of the event

6 Standard SAE Report Form Causality information

7 Case processing Study cases

8 Serious unexpected events in randomized trials What if the patient is taking placebo? General principles: When assigning causality (e.g. for SUSARs), the investigator should assume that the patient is on the study treatment Aim to preserve blinding where possible. Unblind in emergencies only Submit SUSAR report regardless of actual treatment Investigators and sponsor receive blinded SUSAR reports If unblinded+placebo, no SUSAR report is submitted to authorities DSMBs may request unblinded data, while investigator and patient remain blinded

9 Adding `events to the reporter s original list `Events may be added by the company to the reporter s original list, where there are additional symptoms, signs, other medical conditions etc. described in the original fax/ the free text section of the report form the `past history or `concurrent illness section, unless clearly consistent with the reported diagnosis Interpretation of these events is sometimes difficult May not have been of concern to the reporter No `causality information provided by the reporter

10 Reporter s causality assessment Example: One drug, 12 month period Events from study cases: 568/2155 (26%) `not related (2 re-assigned `related by the company) 944/2155 (44%) `related 643/2155 (30%) no reporter causality assessment Events from spontaneous cases: 199/2681 (8%) `not related 1191/2681 (44%) `related 1291/2681 (48%) no reporter causality assessment Note: All spontaneous events are considered `related by the company for reporting purposes

11 Methods for the assessment of individual cases Guidance CIOMS VI (2005): Survey of pharmaceutical companies: 12/21 companies use `introspection, 2 home-grown algorithms, 3 published methods, 4 non- specific methods Recommendations: Binary yes/no causality (i.e. related/not related) for study investigators Grades of causality (e.g. `possible, `probable, `definite ) offer little practical advantage. Only `related versus `unrelated is needed for regulatory reporting requirements Poor inter-rater agreement using terms such as `possible or `probable Investigator should complete a checklist of potential causes Events should be considered related if there is a reasonable possibility of a causal relationship rather than if a causal relationship cannot be ruled out

12 When should an event be considered `related? Guidance FDA (2010) Investigators/sponsors were too cautious in their interpretation of reasonable possibility. They submitted reports for events that were likely to be manifestations of disease, common, probably unrelated events, or study endpoints. FDA received too many SUSAR reports for which there was no evidence of `relatedness. Document provides guidance and examples to illustrate evidence to suggest a causal relationship between the drug and the event. EMA guideline (2012) For regulatory reporting purposes, all spontaneous reports are considered suspected adverse reactions unless the reporters specifically state they believe the events to be unrelated (page 5)

13 Naranjo algorithm at Roche Pre-2001 Home-made algorithm with 6 categories Used to `triage cases for immediate physician review Events from study cases with score 5 `upgraded to `related for regulatory reporting 2009 Naranjo withdrawn Physicians review all cases Events classified `unrelated or `related for regulatory reporting

14 Naranjo algorithm at Roche Survey of cases scored over a 2 year period : Study cases: 43 causality `upgraded because score 5 Spontaneous cases: 12 causality `upgraded because score 5 We now assume `related for all spontaneously reported events unless reporter explicitly states `not related Perceived limitations Little added value Time consuming (strictly, requires a review of previous cases) Information needed to assess probability of a causal relationship depends on the drug-event pair in question (i.e. not the same for all DEPs)

15

16 Expressing causality in words `Problem expressions A causal association cannot be ruled-out A causal association can never be ruled-out by an individual case. It is possible that the event was caused by Drug X Possible has many shades of meaning. Insufficient information for an adequate assessment Often true, but for certain drug-event pairs, no additional information will help assess causality. ICSR is not necessarily helpful for all drug-event pairs. The case was confounded by Risk factors/alternative explanations are not necessarily confounders

17 Assessment of potential new adverse drug reactions Hypothesis (may be a case report, publication etc.) +/- review of other cases? `Drug Safety Report (includes detailed review all relevant information)? Presentation to the Drug Safety Committee -> Decision concerning risk management (including label update etc.) -> Request for additional information etc.

18 Combining evidence from different sources Examples Mechanism of drug action Effects of similar molecules In vitro data Animal studies Pharmacokinetics Clinical trials Observational studies, claims databases etc. Individual case reports

19 Presenting information to the Drug Safety Committee Bradford Hill criteria Austin Bradford Hill. The Environment and Disease: Association or Causation? Proc Royal Soc Med 1965; 58,

20 Single compelling case reports In some instances, one or two case reports can provide compelling evidence of causality, sufficient to change the product label, risk management etc. Examples Progressive multifocal leukoencephalopathy Stevens Johnson syndrome (single case) Fatal anaphylaxis (single case) See also: Anecdotes that provide definitive evidence. Aronson JK, Hauben M. BMJ 2006;333;

21 Conclusions Structured causality assessment methods for individual cases have been used to facilitate case processing rather than to reach definitive conclusions Naranjo algorithm proved to be generally unhelpful Events are considered `related or `not related for the purpose of case processing and regulatory reporting Definitive decisions about causality (leading to RMP/label changes etc.) usually incorporate evidence from various sources Structured approaches e.g. Bradford Hill criteria No single `once size fits all approach Individual case reports sometimes provide compelling evidence of causality

22 Final thoughts Communicating risk (probabilities) to the patient and prescriber Drug attributable risk, effect of time, etc. Listening to the reporter Why do you think the drug caused the event?

23 References Aronson JK, Hauben M. Anecdotes that provide definitive evidence. BMJ 2006; 333; Bradford Hill A. The Environment and disease: association or causation? Proc Royal Soc Med 1965; 58, Naranjo CA, Busto U, Sellers EM, Sandor P et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): Taofikat B. Agbabiaka TB, Savovi J, Ernst E. Methods for causality assessment of adverse drug reactions. A systematic review. Drug Safety 2008; 31 (1): Guidelines for preparing core clinical safety information on drugs. 2 nd Ed. Report of CIOMS Working Groups III and IV. CIOMS Geneva 1999 Management of safety information from clinical trials. Report of CIOMS Working Group VI. CIOMS Geneva 2005 EMA: Guideline on good pharmacovigilance practices (GVP); Module IV Management and reporting of adverse reactions to medicinal products, 20 February 2012; EMA/873138/2011 FDA: Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Sep Drug Safety FDA: Federal Register/Vol75, No 188/Wednesday, September 29, 2010/Rules and Regulations p59945

24 Back-up slides, additional references etc.

25 Guidance Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Sep Drug Safety FDA found that investigators/sponsors were too cautious in their interpretation of reasonable possibility. They submitted reports for events that were likely to be manifestations of disease, common, probably unrelated events, or study endpoints. FDA received too many SUSAR reports for which there was no evidence of `relatedness. Federal Register/Vol75, No 188/Wednesday, September 29, 2010/Rules and Regulations p59945 Examples to illustrate `evidence to suggest a causal relationship between the drug and the adverse event for reporting purposes A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g. angioedema, hepatic injury, SJS) One or more occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug (e.g. tendon rupture) An aggregate analysis of specific events observed in trials (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy), that indicates those events occur more frequently in the drug treatment group than in a concurrent or historic control group

26 Guidance CIOMS VI A CRF is never likely to contain all the fields needed to evaluate causality for all possible types of adverse event (p82) Pre-study training of investigators is very important (p82) Causality assessment for individual SAEs is more relevant for determining regulatory reporting status than for clinical analysis (p120) CIOMS III/V Recommends against expressions in the product label such as The following have been reported, but a causal relationship has not been established, but recognizes some possible advantages to such an approach (p25) Good quality information is essential (p30) The threshold (strength of evidence required) may differ according to the nature and seriousness of the event (p30) No quantitative criteria (such as risk difference >5%) p56 Investigators should always be strongly encouraged to express their opinion on what the cause of an event might be (p56)

27 Guidance ICH E2A ICH E2B The term `adverse reaction implies at least a reasonable possibility of a causal relationship between a suspected product and an adverse event Spontaneously reported events should be considered `related for the purpose of regulatory reporting

28 Capturing the reporter s assessment of causality Proposal #1 Note: Probability categories derived from: Rockey DC, Seeff LB, Rochon J, Freston J et al. for the US Drug-Induced Liver Injury Network. Causality assessment in druginduced liver injury using a structured expert opinion process: Comparison to the roussel-uclaf causality assessment method. Hepatology 2010; 51:

PIPA Guidelines for Signal Management for Small and Medium Sized Pharmaceutical Companies

PIPA Guidelines for Signal Management for Small and Medium Sized Pharmaceutical Companies PIPA Guidelines for Signal Management for Small and Medium Sized Pharmaceutical Companies 03 PIPA Guidelines for Signal Management for Small and Medium Sized Pharmaceutical Companies This document provides

More information

Study Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting

Study Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting M-306.00 SOP for Adverse Event Reporting Study Management SM 306.00 STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature

More information

Tools for Enhanced Pharmacovigilance and Signal Detection in Clinical Trials

Tools for Enhanced Pharmacovigilance and Signal Detection in Clinical Trials Tools for Enhanced Pharmacovigilance and Signal Detection in Clinical Trials Wayne Kubick Phase Forward Lincoln Safety Group Disclaimer The views and opinions expressed in these slides are those of the

More information

Guidance for Industry and Investigators

Guidance for Industry and Investigators Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010

Clinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010 Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured

More information

Guidance for Clinical Investigators, Sponsors, and IRBs

Guidance for Clinical Investigators, Sponsors, and IRBs Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center

More information

Safety Assessment for IND Safety Reporting Guidance for Industry

Safety Assessment for IND Safety Reporting Guidance for Industry Safety Assessment for IND Safety Reporting Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

Perspectives on Social Media for Postmarketing Drug Safety Monitoring

Perspectives on Social Media for Postmarketing Drug Safety Monitoring Perspectives on Social Media for Postmarketing Drug Safety Monitoring The views expressed are those of the speaker and do not necessarily reflect FDA policy. Robert Ball, MD, MPH, ScM Deputy Director Office

More information

PHARMACOVIGILANCE GUIDELINES

PHARMACOVIGILANCE GUIDELINES PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions

More information

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB

More information

Brief Communications. Awad Mohamed Ahmed, MD. Abstract

Brief Communications. Awad Mohamed Ahmed, MD. Abstract Awad Mohamed Ahmed, MD Professor of Medicine, University of Bahr Elghazal, Khartoum, Sudan For correspondence Professor Awad Mohamed Ahmed E-mail: awad.sd@gmail.com Tel.: +249 912344936 Abstract Randomized

More information

Clinical Trials and Safety Surveillance of Drugs in Development

Clinical Trials and Safety Surveillance of Drugs in Development Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical

More information

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Not All Clinical Trials Are Created Equal Understanding the Different Phases Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact

More information

MedDRA in clinical trials industry perspective

MedDRA in clinical trials industry perspective MedDRA in clinical trials industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International

More information

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2): Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS

More information

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011

TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance. Session 1: ICH E9 and E10. PSI Conference, May 2011 TUTORIAL on ICH E9 and Other Statistical Regulatory Guidance Session 1: PSI Conference, May 2011 Kerry Gordon, Quintiles 1 E9, and how to locate it 2 ICH E9 Statistical Principles for Clinical Trials (Issued

More information

Clinical Trials Glossary

Clinical Trials Glossary Clinical Trials Glossary ADME: an acronym for absorption, distribution, metabolism and elimination. ADME studies determine how a drug is absorbed by the body, the chemical changes that it may undergo and

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON CLINICAL SAFETY

More information

Adverse Events in Clinical Trials: Definitions and Documentation

Adverse Events in Clinical Trials: Definitions and Documentation Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions

More information

PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE

PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.

More information

TEMPLATE DATA MANAGEMENT PLAN

TEMPLATE DATA MANAGEMENT PLAN TEMPLATE DATA MANAGEMENT PLAN ICRIN (QM sub group) Version: XX Date: XXXXXXX Page 1 of 6 1.0 Document Ownership The Data Management Plan (DMP) will be initiated and subsequently owned by the Data Manager

More information

How are drugs evaluated in Australia:

How are drugs evaluated in Australia: How are drugs evaluated in Australia: Clinical Trials/Government Regulation A/Prof Noel Cranswick Clinical Pharmacology & APPRU Royal Children s Hospital Melbourne, Victoria. Biologics Control Act, 1902

More information

Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools

Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation;

More information

CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives

CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives Anisa Scott, Ph.D. and Richard C. Zink, Ph.D. JMP Life Sciences SAS Institute, Inc. anisa.scott@jmp.com Copyright 2010 SAS Institute

More information

Data Management in Clinical Trials

Data Management in Clinical Trials Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer

More information

The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd.

The Clinical Trial Protocol Guide. BioStrategics Consulting Ltd. The Clinical Trial Protocol Guide 2011 BioStrategics Consulting Ltd. BioStrategics Consulting Ltd THE CLINICAL TRIAL PROTOCOL The clinical trial protocol to test one s product, to confirm or reject a specific

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes

Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,

More information

POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D

POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS

More information

Workshop on Patient Support and Market Research Programmes

Workshop on Patient Support and Market Research Programmes Workshop on Patient Support and Market Research Programmes Spectrum of programmes falling under the terms of PSP and MRPs and the and the type of safety data collected Pharmaceutical Industry Associations

More information

Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety)

Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety) Pharmacovigilance information for pharmaceutical companies Electronic exchanges of individual case safety reports (ICSRs) with ANSM (National Agency of Medicine and Health Product safety) This document

More information

Medicine Safety Glossary

Medicine Safety Glossary The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive

More information

Guidance on adverse drug reactions

Guidance on adverse drug reactions Guidance on adverse drug reactions Classification of adverse drug reactions Adverse drug reactions are frequently classified as type A and type B reactions. An extended version of this classification system

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL

More information

MedDRA in pharmacovigilance industry perspective

MedDRA in pharmacovigilance industry perspective MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International

More information

Guidance for Industry

Guidance for Industry Guidance for Industry E2F Development Safety Update Report U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics

More information

Research Study Protocol Template

Research Study Protocol Template Research Study Protocol Template (For clinical trials) Instructions This protocol template is a tool to facilitate the development of a research study protocol specifically designed for the investigator

More information

Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG

Risk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation

More information

ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5

ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5 European Medicines Agency June 1995 CPMP/ICH/377/95 ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT:

More information

EphMRA Adverse Event Reporting Guidelines 2015

EphMRA Adverse Event Reporting Guidelines 2015 EphMRA Adverse Event Reporting Guidelines 2015 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European

More information

Adverse Events: Documenting, Recording, and Reporting

Adverse Events: Documenting, Recording, and Reporting Adverse Events: Documenting, Recording, and Reporting Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Introduction Monitoring of adverse

More information

EphMRA Adverse Event Reporting Guidelines 2013

EphMRA Adverse Event Reporting Guidelines 2013 EphMRA Adverse Event Reporting Guidelines 2013 Based upon the Guideline on good pharmacovigilance practices (GVP) Module VI Management and reporting of adverse reactions to medicinal products European

More information

Draft presentation: Summary of product characteristics

Draft presentation: Summary of product characteristics Draft presentation: Summary of product characteristics What is it and what does it contain? Olayinka Fasanya Medical information - Information compliance and consistency An agency of the European Union

More information

Guidance notes on the management of adverse events and product complaints from digital media

Guidance notes on the management of adverse events and product complaints from digital media Guidance notes on the management of adverse events and product complaints from digital media Guidance notes on the management of adverse events and product complaints from digital media ABPI Pharmacovigilance

More information

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes

Guidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May

More information

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy Trial name: HOVON xxx yyy Sponsor: HOVON Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy QRMP authors

More information

Guidance for Pharmaceutical Industry Adverse Drug Reaction Reporting Requirements

Guidance for Pharmaceutical Industry Adverse Drug Reaction Reporting Requirements Guidance for Pharmaceutical Industry Adverse Drug Reaction Reporting Requirements Drug Office Department of Health February 2015 Guidance for Pharmaceutical Industry ADR Reporting Requirements (02/2015)

More information

YOUR GATEWAY TO. EXPERIENCE, quality & FLEXIBILITy

YOUR GATEWAY TO. EXPERIENCE, quality & FLEXIBILITy YOUR GATEWAY TO EXPERIENCE, quality & FLEXIBILITy DATA MANAGEMENT SERVICES The quality of your data defi ne the success of your trial, therefore proper handling of data is fundamental. Our Data Management

More information

Learn More About Product Labeling

Learn More About Product Labeling Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific

More information

Post-authorisation safety studies and the EU PAS Register

Post-authorisation safety studies and the EU PAS Register Post-authorisation safety studies and the EU PAS Register Sixth Stakeholders forum on the implementation of the new legislation Xavier Kurz European Medicines Agency European Medicines Agency, 8 November2012

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Guideline for Industry

Guideline for Industry Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY

More information

DEVELOPMENT SAFETY UPDATE REPORT E2F

DEVELOPMENT SAFETY UPDATE REPORT E2F INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE DEVELOPMENT SAFETY UPDATE REPORT E2F Current Step

More information

June Guide to Important Safety Information. Using GILENYA In Patients with Relapsing Forms of Multiple Sclerosis

June Guide to Important Safety Information. Using GILENYA In Patients with Relapsing Forms of Multiple Sclerosis June 2013 Guide to Important Safety Information Using GILENYA In Patients with Relapsing Forms of Multiple Sclerosis R GILENYA (fingolimod) is a sphingosine 1-phosphate receptor (S1P) modulator indicated

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions

More information

The use of the WHO-UMC system for standardised case causality assessment

The use of the WHO-UMC system for standardised case causality assessment The use of the WHO-UMC system for standardised case causality assessment Why causality assessment? An inherent problem in pharmacovigilance is that most case reports concern suspected adverse drug reactions.

More information

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP

OBSERVATIONAL MEDICAL OUTCOMES PARTNERSHIP OBSERVATIONAL Opportunities for Signal Detection in an Active Surveillance System Andrew Bate Pfizer, Senior Director, Analytics Team Lead Epidemiology OMOP January 2011 Symposium Contents Background Signal

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies Appendix I of the Guidelines for the Clinical Translation of Stem Cells www.isscr.org 2008, International Society for Stem Cell Research 2 Introduction We have all

More information

GT-020 Phase 1 Clinical Trial: Results of Second Cohort

GT-020 Phase 1 Clinical Trial: Results of Second Cohort GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in

More information

Clinical Trials Patient-Education Brochure

Clinical Trials Patient-Education Brochure Release Date November 2005 Revised January 2008 Revised March 2012 Clinical Trials Patient-Education Brochure American Society of Transplantation 1120 Route 73, Suite 200 Mount Laurel, NJ 08054 Phone:

More information

Clinical Research Definitions and Procedures

Clinical Research Definitions and Procedures Clinical Research Definitions and Procedures Steven Hirschfeld MD PhD Associate Director for Clinical Research National Institute of Child Health and Human Development U.S. DEPARTMENT OF HEALTH AND HUMAN

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

Life Cycle Risk Management. Barton Cobert, MD, FACP, FACG BLCMD Associates LLC December 2013

Life Cycle Risk Management. Barton Cobert, MD, FACP, FACG BLCMD Associates LLC December 2013 Life Cycle Risk Management Barton Cobert, MD, FACP, FACG BLCMD Associates LLC December 2013 1 Premarketing vs Postmarketing Risk Assessment The concepts of risk assessment and minimization are better developed

More information

A clinical research organization

A clinical research organization A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

Assessment of Rescue Medication Effect in Psychiatric Clinical Trials

Assessment of Rescue Medication Effect in Psychiatric Clinical Trials Society for Clinical Trials 36 th Annual Meeting Assessment of Rescue Medication Effect in Psychiatric Clinical Trials Zhibao Mi, John H. Krystal, Karen M. Jones, Robert A. Rosenheck, Joseph F. Collins

More information

The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial

The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial The Consequences of Missing Data in the ATLAS ACS 2-TIMI 51 Trial In this white paper, we will explore the consequences of missing data in the ATLAS ACS 2-TIMI 51 Trial and consider if an alternative approach

More information

Introduction. Ethical Issues in the Statistical Analysis of Clinical Research Data. Introduction. Introduction. Statistical Quality or Ethical Degree

Introduction. Ethical Issues in the Statistical Analysis of Clinical Research Data. Introduction. Introduction. Statistical Quality or Ethical Degree Ethical Issues in the Statistical Analysis of Clinical Research Data Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center Torrance, California Introduction Types of data-centered

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1

EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter

More information

Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6)

Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Tip Sheet 11: Following the Guideline of the International Conference on Harmonization Good Clinical Practice (E6) Related Accreditation Elements: I.1.D., I.1.F., I-2, I.7.B., II.2.E., II.2.F., II.4.A.,

More information

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials

More information

Questions and Answers to the Annual Safety Report

Questions and Answers to the Annual Safety Report Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit

More information

Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals

Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals Pharmacovigilance costs 0.12%-0.22% of hospital admissions

More information

SUSPECT ADVERSE REACTION REPORT

SUSPECT ADVERSE REACTION REPORT CIOMS FORM SUSPECT ADVERSE REACTION REPORT DE-BFARM-16312652 I. REACTION INFORMATION 1. PATIENT INITIALS 1a. COUNTRY 2. DATE OF BIRTH 2a. AGE 3. SEX 4-6 REACTION ONSET privacy DE DA MO YR Female Kniegelenkserguss

More information

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8

GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current

More information

Subject: Tecfidera (dimethyl fumarate): new measures to minimise the risk of PML enhanced monitoring and stopping rules

Subject: Tecfidera (dimethyl fumarate): new measures to minimise the risk of PML enhanced monitoring and stopping rules Date: 25 th November 2015 Subject: Tecfidera (dimethyl fumarate): new measures to minimise the risk of PML enhanced monitoring and stopping rules Dear Healthcare Professional In agreement with the European

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Investigational Drugs: Investigational Drugs and Biologics

Investigational Drugs: Investigational Drugs and Biologics : I. PURPOSE The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics to ensure that adequate safeguards are in place

More information

Regulations & Requirements for Conducting Clinical Trials on Drugs

Regulations & Requirements for Conducting Clinical Trials on Drugs Regulations & Requirements for Conducting Clinical Trials on Drugs Version 1.0 Date issued Date of implementation 08/07/2015 08/07/2015 1 [SFDA Regulations & Requirements for Conducting Clinical Trials

More information

ICRIN Seminar on EU Regulation of Clinical Trials

ICRIN Seminar on EU Regulation of Clinical Trials ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation

More information

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) 9 December 2013 EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII Periodic safety update report (Rev 1) Date for coming into effect of first version 2 July 2012 Draft

More information

Taking Part in Cancer Treatment Research Studies

Taking Part in Cancer Treatment Research Studies National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health This booklet is for people with cancer, their family,

More information

EBM Cheat Sheet- Measurements Card

EBM Cheat Sheet- Measurements Card EBM Cheat Sheet- Measurements Card Basic terms: Prevalence = Number of existing cases of disease at a point in time / Total population. Notes: Numerator includes old and new cases Prevalence is cross-sectional

More information

EudraVigilance stakeholder change management plan

EudraVigilance stakeholder change management plan 26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation

More information

Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs)

Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) London, 21 April 2009 Doc. Ref. EMA/13432/2009 Committee for Medicinal Products for Human Use (CHMP) Guideline on Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports

More information

The Product Review Life Cycle A Brief Overview

The Product Review Life Cycle A Brief Overview Stat & Quant Mthds Pharm Reg (Spring 2, 2014) Lecture 2,Week 1 1 The review process developed over a 40 year period and has been influenced by 5 Prescription User Fee Act renewals Time frames for review

More information

When Does it Make Sense to Perform a Meta-Analysis?

When Does it Make Sense to Perform a Meta-Analysis? CHAPTER 40 When Does it Make Sense to Perform a Meta-Analysis? Introduction Are the studies similar enough to combine? Can I combine studies with different designs? How many studies are enough to carry

More information

E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report Questions & Answers

E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report Questions & Answers E2C(R2) Implementation Working Group ICH E2C(R2) Guideline: Periodic Benefit-Risk Evaluation Report & Current version dated 31 March International Conference on Harmonisation of Technical Requirements

More information

CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN

CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN Document CEN TC 258/WG2 N15 (Draft # 6, June 2000) CEN TC 258 Committee Enquiry/ISO TC 194 Committee Draft EN ISO 14155 CLINICAL INVESTIGATION OF MEDICAL DEVICES FOR HUMAN SUBJECTS PART 2: CLINICAL INVESTIGATION

More information

Reporting of Adverse Events and Unanticipated Problems

Reporting of Adverse Events and Unanticipated Problems Reporting of Adverse Events and Unanticipated Problems Policy date: 12/2011 Purpose The purpose of this policy is to ensure that the review, reporting and analysis of adverse events and unanticipated problems

More information

An Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods

An Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods An Evidence-Based Approach to Reviewing the Science on the Safety of Chemicals in Foods In considering the safety of chemicals added to foods, or present in foods due to environmental circumstances, we

More information

Glossary of Clinical Trial Terms

Glossary of Clinical Trial Terms Glossary of Clinical Trial Terms ADVERSE REACTION: (Adverse Event): Also known as side effects, adverse reactions include any undesired actions or effects of the experimental drug or treatment. Experimental

More information

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India.

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION TO CLINICAL TRIAL Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION The safety and toxicity data generated from

More information

Risk Management Plan (RMP) Guidance (Draft)

Risk Management Plan (RMP) Guidance (Draft) Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour

More information

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's

More information

GUIDELINES ON MEDICAL DEVICES

GUIDELINES ON MEDICAL DEVICES EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON

More information

Medical Dictionary for Regulatory Activities (MedDRA) Update

Medical Dictionary for Regulatory Activities (MedDRA) Update Medical Dictionary for Regulatory Activities (MedDRA) Update International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Topics MedDRA as an ICH

More information